CLINICAL TRIALS PROFILE FOR REVATIO

All Clinical Trials for Revatio

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00359736 ↗	Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis	Completed	VA Office of Research and Development	Phase 2	2006-07-01	Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.
NCT00452218 ↗	Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)	Completed	Bayer	Phase 1	2007-03-01	The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00452218 ↗	Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)	Completed	University of Chicago	Phase 1	2007-03-01	The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00507819 ↗	Sildenafil After the Fontan Operation	Completed	The Mark H. and Blanche M. Harrington Foundation	Phase 2	2007-12-01	In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.
NCT00507819 ↗	Sildenafil After the Fontan Operation	Completed	Children's Hospital of Philadelphia	Phase 2	2007-12-01	In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.

Clinical Trial Conditions for Revatio

Condition Name

Condition Name for Revatio
Intervention	Trials
Pulmonary Arterial Hypertension	9
Pulmonary Hypertension	7
Hypertension, Pulmonary	5
Heart Failure	3

Condition MeSH

Condition MeSH for Revatio
Intervention	Trials
Hypertension	24
Hypertension, Pulmonary	17
Pulmonary Arterial Hypertension	12
Familial Primary Pulmonary Hypertension	10

Clinical Trial Locations for Revatio

Trials by Country

Trials by Country for Revatio
Location	Trials
United States	120
Germany	18
Canada	14
Spain	8
Belgium	7

Trials by US State

Trials by US State for Revatio
Location	Trials
North Carolina	10
California	8
New York	7
Texas	6
Ohio	6

Clinical Trial Progress for Revatio

Clinical Trial Phase

Clinical Trial Phase for Revatio
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Revatio
Clinical Trial Phase	Trials
Completed	41
Terminated	9
Recruiting	7

Clinical Trial Sponsors for Revatio

Sponsor Name

Sponsor Name for Revatio
Sponsor	Trials
Pfizer	17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	8
National Heart, Lung, and Blood Institute (NHLBI)	8

Sponsor Type

Sponsor Type for Revatio
Sponsor	Trials
Other	78
Industry	36
NIH	15